2 results
Approved WMOCompleted
To determine which bowel preparation product is superior in cleansing the colon and in patient satisfaction.
Approved WMOCompleted
The primary hypothesis of this study is that ibrutinib compared with temsirolimus significantly prolongs PFS in subjects with relapsed or refractory MCL who have received at least 1 prior rituximab-containing chemotherapy regimen.